Search by Drug Name or NDC
NDC 51267-0890-07 Contrave 90; 8 mg/1; mg/1 Details
Contrave 90; 8 mg/1; mg/1
Contrave is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Nalpropion Pharmaceuticals LLC. The primary component is BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE.
MedlinePlus Drug Summary
The combination of naltrexone and bupropion is used along with a reduced calorie diet and exercise plan to help adults who are obese, or who are overweight and have weight-related medical problems, to lose weight and then to keep from gaining back that weight. Naltrexone is in a class of medications called opiate antagonists. Bupropion is in a class of medications called antidepressants. These medications work together on two areas of the brain, the hunger center and the reward system, to reduce appetite and help control cravings.
Related Packages: 51267-0890-07Last Updated: 04/14/2024
MedLinePlus Full Drug Details: Naltrexone and Bupropion
Product Information
| NDC | 51267-0890 |
|---|---|
| Product ID | 51267-890_ab1b082f-fd25-43f7-b7ea-13a34aa05cc2 |
| Associated GPIs | 61259902507420 |
| GCN Sequence Number | 072802 |
| GCN Sequence Number Description | naltrexone HCl/bupropion HCl TABLET ER 8 MG-90 MG ORAL |
| HIC3 | J8D |
| HIC3 Description | ANTI-OBESITY-OPIOID ANTAG-NOREPI,DOPAMINE RU INHIB |
| GCN | 37096 |
| HICL Sequence Number | 041389 |
| HICL Sequence Number Description | NALTREXONE HCL/BUPROPION HCL |
| Brand/Generic | Brand |
| Proprietary Name | Contrave |
| Proprietary Name Suffix | Extended-Release |
| Non-Proprietary Name | naltrexone hydrochloride and bupropion hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 90; 8 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE |
| Labeler Name | Nalpropion Pharmaceuticals LLC |
| Pharmaceutical Class | Aminoketone [EPC], Dopamine Uptake Inhibitors [MoA], Increased Dopamine Activity [PE], Increased Norepinephrine Activity [PE], Norepinephrine Uptake Inhibitors [MoA], Opioid Antagonist [EPC], Opioid Antagonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA200063 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 51267-0890-07 (51267089007)
| NDC Package Code | 51267-890-07 |
|---|---|
| Billing NDC | 51267089007 |
| Package | 7 TABLET, EXTENDED RELEASE in 1 BOTTLE (51267-890-07) |
| Marketing Start Date | 2021-01-14 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |